Equillium (LTS:0A4D) Additional Paid-In Capital : $212.31 Mil(As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Equillium Additional Paid-In Capital?

Equillium's quarterly additional paid-in capital increased from Sep. 2024 ($211.19 Mil) to Dec. 2024 ($212.08 Mil) and increased from Dec. 2024 ($212.08 Mil) to Mar. 2025 ($212.31 Mil).

Equillium's annual additional paid-in capital increased from Dec. 2022 ($204.27 Mil) to Dec. 2023 ($208.17 Mil) and increased from Dec. 2023 ($208.17 Mil) to Dec. 2024 ($212.08 Mil).

Equillium Additional Paid-In Capital Historical Data

The historical data trend for Equillium's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Additional Paid-In Capital Chart

Equillium Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

141.07

176.62

204.27

208.17

212.08

Equillium Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															209.14	210.19	211.19	212.08	212.31

Equillium Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Equillium Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Equillium's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Equillium Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (LTS:0A4D) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

EQ:USA 0FY:Germany

Address

2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037

Website

https://www.equilliumbio.com

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Equillium Headlines

No Headlines